Intrathecal inflammation precedes development of Alzheimer's disease

E Tarkowski, N Andreasen, A Tarkowski, K Blennow, E Tarkowski, N Andreasen, A Tarkowski, K Blennow

Abstract

Objectives: To analyse the cerebrospinal fluid (CSF) values of the proinflammatory cytokines, interleukin 1beta (IL1beta), tumour necrosis factor alpha (TNFalpha), GM-CSF, of the anti-inflammatory cytokine TGFbeta, of tau protein, a marker for neurodegeneration, and of beta amyloid (Abeta), a protein involved in the formation of senile plaques, in prospectively followed up patients with mild cognitive impairment (MCI).

Methods: Analyses of CSF levels of TNFalpha, IL1beta, GM-CSF, TGFbeta, betaa, and tau protein were performed using ELISA in 56 patients with MCI who were followed up prospectively and in 25 age matched, healthy controls.

Results: Patients with MCI displayed significantly higher levels of TNFalpha and tau protein and significantly lower levels of TGFbeta and Abeta compared with the healthy controls. After nine months of follow up, 25 patients still displayed MCI while the remaining 31 patients had progressed to Alzheimer's disease (AD). Only MCI patients who progressed to AD at follow up, showed significantly higher CSF levels of TNFalpha than controls. In addition, reduced CSF-Abeta42 levels were only found in MCI patients that progressed to AD, further supporting the notion that disturbed metabolism of Abeta is an early finding in AD.

Conclusions: These results demonstrate increased production of the proinflammatory cytokine, TNFalpha and decreased production of the anti-inflammatory cytokine TGFbeta in patients with MCI at risk to develop AD, suggesting a propensity towards inflammation in this patient group and indicating that CNS inflammation is a early hallmark in the pathogenesis of AD.

References

    1. J Neurosurg. 2000 Jan;92(1):108-20
    1. Neurosci Lett. 1999 Sep 24;273(1):5-8
    1. Neurology. 2000 Jun 13;54(11):2077-81
    1. Neurobiol Aging. 2000 May-Jun;21(3):383-421
    1. Acta Neurol Scand. 2001 Mar;103(3):166-74
    1. Neurobiol Aging. 2002 Mar-Apr;23(2):237-43
    1. J Psychiatr Res. 1975 Nov;12(3):189-98
    1. Neurology. 1984 Jul;34(7):939-44
    1. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9
    1. Neurosci Lett. 1987 Aug 18;79(1-2):195-200
    1. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7606-10
    1. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7611-5
    1. Can J Neurol Sci. 1989 Nov;16(4 Suppl):516-27
    1. Endocrinology. 1991 Jul;129(1):562-4
    1. Brain Res. 1991 Apr 5;545(1-2):334-8
    1. Immunol Today. 1991 Jul;12(7):217-9
    1. Immunol Today. 1991 Nov;12(11):404-10
    1. Brain Res Bull. 1992 Aug;29(2):243-6
    1. Res Immunol. 1992 Jul-Aug;143(6):650-7
    1. Glia. 1993 Jan;7(1):75-83
    1. J Immunol. 1993 Aug 15;151(4):2150-8
    1. Neuron. 1994 Jan;12(1):139-53
    1. JAMA. 1995 Apr 26;273(16):1274-8
    1. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9328-32
    1. Int J Dev Neurosci. 1995 Jun-Jul;13(3-4):341-9
    1. J Biol Chem. 1996 Jan 12;271(2):603-6
    1. Cancer Lett. 1996 Apr 19;102(1-2):209-15
    1. Stroke. 1996 May;27(5):852-7
    1. Mol Chem Neuropathol. 1995 Dec;26(3):231-45
    1. JAMA. 1997 Mar 12;277(10):813-7
    1. Nature. 1997 Oct 9;389(6651):603-6
    1. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):298-305
    1. Arch Neurol. 1998 Jul;55(7):937-45
    1. Glia. 1998 Oct;24(2):216-25
    1. Arch Neurol. 1999 Jun;56(6):673-80
    1. J Clin Immunol. 1999 Jul;19(4):223-30
    1. J Submicrosc Cytol Pathol. 1999 Jul;31(3):313-23

Source: PubMed

3
Suscribir